142 related articles for article (PubMed ID: 21458847)
1. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
[TBL] [Abstract][Full Text] [Related]
2. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
4. Biochemical studies on sulfated lactobionic acid amides.
Klauser RJ; Meinetsberger E; Raake W
Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
[TBL] [Abstract][Full Text] [Related]
5. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
6. The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.
Ammollo CT; Semeraro F; Semeraro N; Colucci M
Thromb Haemost; 2009 Apr; 101(4):782-5. PubMed ID: 19350129
[No Abstract] [Full Text] [Related]
7. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
8. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Ofosu FA; Smith LM; Anvari N; Blajchman MA
Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
Harenberg J
J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
[TBL] [Abstract][Full Text] [Related]
10. Facts and artefacts of coagulation assays for factor Xa inhibitors.
Haas S
Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
[No Abstract] [Full Text] [Related]
11. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
Barrowcliffe TW; Thomas DP
Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
[TBL] [Abstract][Full Text] [Related]
13. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
Martínez-González J; Vila L; Rodríguez C
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
[TBL] [Abstract][Full Text] [Related]
14. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
[TBL] [Abstract][Full Text] [Related]
16. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
17. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
18. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
Stief TW
Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
[TBL] [Abstract][Full Text] [Related]
20. Effects of a heparin-binding protein on blood coagulation and platelet function.
Kaiser P; Harenberg J; Walenga JM; Huhle G; Giese C; Prechel M; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 2001 Oct; 27(5):495-502. PubMed ID: 11668419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
